Lv Linlin, Yang Shilei, Zhu Yanna, Zhai Xiaohan, Li Shuai, Tao Xufeng, Dong Deshi
Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.
School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China.
Front Oncol. 2022 Aug 18;12:942064. doi: 10.3389/fonc.2022.942064. eCollection 2022.
Breast cancer is the leading cause of cancer death in women. At present, chemotherapy is the main method to treat breast cancer in addition to surgery and radiotherapy, but the process of chemotherapy is often accompanied by the development of drug resistance, which leads to a reduction in drug efficacy. Furthermore, mounting evidence indicates that drug resistance is caused by dysregulated cellular metabolism, and metabolic reprogramming, including enhanced glucose metabolism, fatty acid synthesis and glutamine metabolic rates, is one of the hallmarks of cancer. Changes in metabolism have been considered one of the most important causes of resistance to treatment, and knowledge of the mechanisms involved will help in identifying potential treatment deficiencies. To improve women's survival outcomes, it is vital to elucidate the relationship between metabolic reprogramming and drug resistance in breast cancer. This review analyzes and investigates the reprogramming of metabolism and resistance to breast cancer therapy, and the results offer promise for novel targeted and cell-based therapies.
乳腺癌是女性癌症死亡的主要原因。目前，化疗是除手术和放疗外治疗乳腺癌的主要方法，但化疗过程中常伴随着耐药性的产生，导致药物疗效降低。此外，越来越多的证据表明，耐药性是由细胞代谢失调引起的，而代谢重编程，包括增强的葡萄糖代谢、脂肪酸合成和谷氨酰胺代谢率，是癌症的特征之一。代谢变化被认为是治疗耐药的最重要原因之一，了解其中涉及的机制将有助于识别潜在的治疗缺陷。为了改善女性的生存结果，阐明乳腺癌中代谢重编程与耐药性之间的关系至关重要。本综述分析和研究了乳腺癌治疗中的代谢重编程和耐药性，其结果为新型靶向治疗和基于细胞的治疗带来了希望。
